AdaptHealth Corp. (NASDAQ:AHCO) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of AdaptHealth Corp. (NASDAQ:AHCO) have been given a consensus rating of “Moderate Buy” by the six analysts that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $14.25.

Several brokerages recently commented on AHCO. Zacks Research upgraded shares of AdaptHealth from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Canaccord Genuity Group raised their price objective on AdaptHealth from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Wall Street Zen downgraded AdaptHealth from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Finally, Weiss Ratings raised AdaptHealth from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, January 30th.

Insider Buying and Selling at AdaptHealth

In other news, Director David Solomon Williams III sold 5,000 shares of the stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $9.43, for a total value of $47,150.00. Following the completion of the sale, the director directly owned 45,045 shares of the company’s stock, valued at approximately $424,774.35. This represents a 9.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.55% of the company’s stock.

Institutional Trading of AdaptHealth

A number of large investors have recently bought and sold shares of AHCO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in AdaptHealth by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 60,495 shares of the company’s stock worth $656,000 after purchasing an additional 2,564 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of AdaptHealth by 32.4% during the first quarter. Goldman Sachs Group Inc. now owns 571,232 shares of the company’s stock worth $6,192,000 after buying an additional 139,828 shares during the period. Woodline Partners LP purchased a new position in shares of AdaptHealth during the first quarter worth about $2,851,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in AdaptHealth by 18.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 233,780 shares of the company’s stock valued at $2,534,000 after acquiring an additional 35,879 shares during the period. Finally, CWM LLC raised its stake in AdaptHealth by 1,562.1% during the 2nd quarter. CWM LLC now owns 10,471 shares of the company’s stock valued at $99,000 after acquiring an additional 9,841 shares during the last quarter. Institutional investors and hedge funds own 82.67% of the company’s stock.

AdaptHealth Price Performance

AHCO stock opened at $8.85 on Wednesday. The business has a 50 day moving average price of $10.24 and a 200 day moving average price of $9.66. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of 16.09, a PEG ratio of 1.17 and a beta of 1.72. AdaptHealth has a fifty-two week low of $7.11 and a fifty-two week high of $11.63.

AdaptHealth (NASDAQ:AHCO) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of $0.34 by ($1.10). The company had revenue of $846.29 million during the quarter, compared to analysts’ expectations of $832.51 million. AdaptHealth had a net margin of 2.53% and a return on equity of 4.85%. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.34 earnings per share. Equities research analysts anticipate that AdaptHealth will post 0.88 earnings per share for the current fiscal year.

Key Headlines Impacting AdaptHealth

Here are the key news stories impacting AdaptHealth this week:

• Positive Sentiment: Revenue beat consensus: AdaptHealth reported quarterly revenue of $846.3M, above the $832.5M consensus, showing modest top-line resilience despite year‑over‑year revenue decline. Read More.
• Positive Sentiment: Operational highlights: The company said it set patient‑census records in Sleep Health, Respiratory Health and Wellness at Home, which could support future recurring revenue and retention. Read More.
• Neutral Sentiment: Earnings materials available: The Q4 2025 earnings call transcript and the investor presentation were published (useful for digging into segment trends and management commentary). Read More. • Read More.
• Neutral Sentiment: Short‑interest note appears to be a reporting error: a February report showed “0 shares” and NaN changes — not actionable evidence of a short squeeze or heavy shorting. (Data looks unreliable.)
• Negative Sentiment: Large EPS miss and profitability weakness: Analysts expected roughly $0.34 EPS; coverage and the company reported results that missed estimates and showed a sharp decline from the prior year, weighing on investor confidence. Read More.
• Negative Sentiment: Guidance ambiguity: The company’s FY‑2026 disclosure lacked a clear EPS target (and provided a revenue range roughly in line with street expectations), which likely increased uncertainty around near‑term profitability. Read More.

About AdaptHealth

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.